METHODS: We conducted a proof-of-concept in vitro study to assess the ADVOS multi system\'s efficacy in eliminating IL-6. Varying concentrations of IL-6 were introduced into a swine blood model and treated with ADVOS multi for up to 12 h, employing different blood and concentrate flow rates. IL-6 reduction rate, clearance, and dynamics in blood and dialysate were analyzed.
RESULTS: IL-6 clearance rates of 0.70 L/h and 0.42 L/h were observed in 4 and 12-h experiments, respectively. No significant differences were noted across different initial concentrations. Reduction rates ranged between 40 and 46% within the first 4 h, increasing up to 72% over 12 h, with minimal impact from flow rate variations. Our findings suggest that an IL-6-albumin interaction and convective filtration are implicated in in vitro IL-6 elimination with ADVOS multi.
CONCLUSIONS: This study demonstrates for the first time an efficient and continuous in vitro removal of IL-6 by ADVOS multi at low blood flow rates. Initial concentration-dependent removal transitions to more consistent elimination over time. Further clinical investigations are imperative for comprehensive data acquisition.
方法:我们进行了一项体外概念验证研究,以评估ADVOS多系统在消除IL-6方面的功效。将不同浓度的IL-6引入猪血模型中,并用ADVOS多药处理长达12小时,采用不同的血液和浓缩液流速。IL-6降低率,间隙,并对血液和透析液中的动力学进行了分析。
结果:在4和12小时实验中观察到IL-6清除率为0.70L/h和0.42L/h,分别。在不同的初始浓度之间没有注意到显著差异。在最初的4小时内,减少率介于40%和46%之间,在12小时内增加高达72%,从流量变化的影响最小。我们的发现表明,IL-6-白蛋白相互作用和对流过滤与ADVOS多重体外IL-6消除有关。
结论:这项研究首次证明了在低血流速率下,ADVOSmulti在体外有效且连续地去除IL-6。随着时间的推移,初始浓度依赖性去除过渡到更一致的消除。进一步的临床研究对于全面的数据采集至关重要。